SLN
Silence Therapeutics plc
NASDAQ · Healthcare · Biotechnology · GB
$14.59
−1.35%Aug 10, 2026, 20:01 UTC
Silence Therapeutics announced the commencement of an underwritten public offering of approximately $150 million of its American Depositary Shares in the United States.
Aug 10, 2026, 11:31 UTC
Silence Therapeutics announced Phase 2 trial results for its experimental drug divesiran in polycythemia vera, showing 88% clinical response rate versus 19% for placebo, positioning it to compete with Takeda's near-approval drug.
Aug 10, 2026, 00:00 UTC
Silence Therapeutics plc reported its Q2 2026 financial results, with zero revenue, a net loss of $12.3 million, and diluted loss per share of $0.09, compared to a net loss of $27.4 million in Q2 2025.
Jun 12, 2026, 14:47 UTC
Silence Therapeutics Plc highlighted follow-up data from its Phase 1 SANRECO study of divesiran.
Source: